5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | BUY | BUY | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 4.41▲ | 4.41▲ | 4.41▲ | 4.44▼ | 4.27▲ |
MA10 | 4.39▲ | 4.40▲ | 4.40▲ | 4.43▼ | 4.98▼ |
MA20 | 4.45▲ | 4.47▲ | 4.48▲ | 4.29▲ | 5.67▼ |
MA50 | 4.37▲ | 4.32▲ | 4.28▲ | 5.13▼ | 6.29▼ |
MA100 | 4.28▲ | 4.40▲ | 4.62▼ | 5.80▼ | 9.25▼ |
MA200 | 4.78▼ | 5.12▼ | 5.32▼ | 6.32▼ | 47.52▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.004▼ | -0.010▼ | -0.009▼ | 0.076▲ | -0.136▼ |
RSI | 56.556▲ | 56.309▲ | 55.908▲ | 44.364▼ | 35.555▼ |
STOCH | 62.374 | 49.186 | 38.483 | 60.444 | 19.154▼ |
WILL %R | 0.000▲ | -50.000 | -52.941 | -35.652 | -74.260 |
CCI | 246.321▲ | 140.495▲ | 43.228 | 39.996 | -75.638 |
▲ GAP | $KZR Open Gap Up %2 | Set Alert |
Friday, April 25, 2025 10:19 AM
Investing.com - Kezar Life (NASDAQ: KZR) reported third quarter EPS of $-0.320, $0.04 better than the analyst estimate of $-0.356.
|
Monday, April 14, 2025 05:00 PM
SOUTH SAN FRANCISCO, Calif., March 25, 2025--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune ...
|
Friday, March 28, 2025 05:00 PM
Kezar Life Sciences, Inc. (NASDAQ:KZR – Free Report) – Analysts at William Blair issued their Q1 2026 earnings per share estimates for Kezar Life Sciences in a report released on Tuesday ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
01/05/25 | 4.505 | 4.618 | 4.40 | 4.40 | 5,237 |
30/04/25 | 4.45 | 4.45 | 4.38 | 4.38 | 4,236 |
29/04/25 | 4.42 | 4.45 | 4.34 | 4.39 | 4,755 |
28/04/25 | 4.70 | 4.75 | 4.33 | 4.33 | 12,095 |
25/04/25 | 4.725 | 4.725 | 4.70 | 4.70 | 5,419 |
24/04/25 | 4.57 | 4.81 | 4.52 | 4.75 | 26,240 |
23/04/25 | 4.60 | 4.70 | 4.52 | 4.58 | 7,528 |
22/04/25 | 4.285 | 4.5599 | 4.285 | 4.50 | 15,915 |
21/04/25 | 4.10 | 4.26 | 4.015 | 4.15 | 23,136 |
17/04/25 | 4.142 | 4.32 | 4.11 | 4.16 | 6,491 |
|
|
||||
|
|
||||
|
|